(Q36464014)

14 August 2017

1 reference

title

Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients (English)

1 reference

14 August 2017

0 references

1 reference

Joan Brunet Vidal

2

0 references

author name string

Vicente Valentí Moreno

1

1 reference

14 August 2017

Hermini Manzano Alemany

3

1 reference

14 August 2017

Antonia Salud Salvia

4

1 reference

14 August 2017

Montserrat Llobera Serentill

5

1 reference

14 August 2017

Inés Cabezas Montero

6

1 reference

14 August 2017

Sonia Servitja Tormo

7

1 reference

14 August 2017

Eugenia Sopena Bert

8

1 reference

14 August 2017

Josep Gumà Padró

9

1 reference

14 August 2017

publication date

1 March 2006

1 reference

Clinical and Translational Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

8

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

208-212

1 reference

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

14 August 2017

cites work

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

12 December 2020

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

1 reference

12 December 2020

Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

1 reference

12 December 2020

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity

1 reference

12 December 2020

Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

1 reference

12 December 2020

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

12 December 2020

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

1 reference

12 December 2020

pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers

1 reference

12 December 2020

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

1 reference

12 December 2020

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

12 December 2020

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

1 reference

12 December 2020

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

1 reference

12 December 2020

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

12 December 2020

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients

1 reference

12 December 2020

10.1007/S12094-006-0012-1

Identifiers

DOI

1 reference

14 August 2017

1 reference